# **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

QRxPharma Limited (QRxPharma)

ABN

16 102 254 151

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Class of +securities issued or to be issued

Options over Ordinary Shares.

- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
   2,095,000 Options
- 3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Options issued pursuant to QRxPharma Limited Employee Share Option Plan:

600,000 Options with an exercise price of \$1.00 and an expiry date of 7 November 2019.

280,000 Options with an exercise price of \$1.03 and an expiry date of 7 November 2016.

1,215,000 Options with an exercise price of \$0.72 and an expiry date of 7 November 2019.

4	Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities? If the additional securities do not	Yes – upon exercise of Op	tions.
	<ul> <li>additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
5	Issue price or consideration	\$nil	
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Directors of the Com	Pharma Annual General
		Chief Executive Officer	at the QRxPharma Annual
			d to existing employees, dvisory board members as
7	Dates of entering <sup>+</sup> securities into uncertificated holdings or despatch of certificates	7 November 2012	
		Neurober	+Class
0		Number	+Class
8	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 2 if applicable)	144,577,206	Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

	Number	<sup>+</sup> Class
9. Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX	295,000	Options with an exercise price of \$1.26 and an expiry date of 24 March 2014;
( <i>including</i> the securities in clause 2 if applicable)	402,726	Options with an exercise price of \$1.42 and expiry date of 31 March 2014;
	2,013,630	Options with an exercise price of \$1.00 and expiry date of 14 April 2014;
	1,398,450	Options with an exercise price of \$2.00 and expiry date of 25 May 2014;
	502,726	Options with an exercise price of \$1.00 and expiry date of 25 May 2014;
	50,000	Options with an exercise price of \$1.70 and expiry date of 1 September 2014;
	75,000	Options with an exercise price of \$1.45 and expiry date of 1 October 2014;
	50,000	Options with an exercise price of \$1.34 and an expiry date of 9 October 2014;
	25,000	Options with an exercise price of \$1.27 and an expiry date of 25 October 2014;
	200,000	Options with an exercise price of \$1.11 and an expiry date of 1 January 2015;
	310,000	Options with an exercise price of \$2.00 and an expiry date of 1 January 2015;
	600,000	Options with an exercise price of \$1.05 and an expiry date of 1 April 2015;
	75,000	Options with an exercise price of \$1.04 and an expiry date of 1 April 2015;
	100,000	Options with an exercise price of \$0.20 and an expiry date of 1 January 2016;
	300,000	Options with an exercise price of \$2.15 and an expiry date of 23 January 2016;
	334,650	Options with an exercise price of \$0.65 and an expiry date of 31 August 2016;
	150,000	Options with an exercise price of \$0.90 and an expiry date of 1 October 2016;
	280,000	Options with an exercise price of \$1.03 and an expiry date of 7 November 2016.
	300,000	Options with an exercise price of \$1.12 and an expiry date of 16 November 2016;

Number	<sup>+</sup> Class
100,000	Options with an exercise price of \$0.78 and an expiry date of 1 January 2017;
460,834	Options with an exercise price of \$0.84 and an expiry date of 17 February 2017;
225,000	Options with an exercise price of \$1.15 and an expiry date of 1 July 2017;
50,000	Options with an exercise price of \$0.95 and an expiry date of 24 August 2017;
150,000	Options with an exercise price of \$0.93 and an expiry date of 4 October 2017;
850,000	Options with an exercise price of \$1.00 and an expiry date of 8 November 2017;
1,320,000	Options with an exercise price of \$1.40 and an expiry date of 1 January 2018;
150,000	Options with an exercise price of \$1.70 and an expiry date of 7 July 2018;
15,000	Options with an exercise price of \$1.22 and an expiry date of 28 September 2018;
250,000	Options with an exercise price of \$1.60 and an expiry date of 16 November 2018;
1,400,000	Options with an exercise price of \$1.50 and an expiry date of 23 January 2019;
350,000	Options with an exercise price of \$1.72 and an expiry date of 1 April 2019.
600,000	Options with an exercise price of \$1.00 and an expiry date of 7 November 2019.
1,215,000	Options with an exercise price of \$0.72 and an expiry date of 7 November 2019.
	100,000 460,834 225,000 50,000 150,000 850,000 1,320,000 15,000 15,000 250,000 1,400,000 350,000 600,000

<sup>+</sup> See chapter 19 for defined terms.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Number	+Class	
N/A		

# Part 2 - Bonus issue or pro rata issue – Not Applicable

11	Is security holder approval required?
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the <sup>+</sup> securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has <sup>+</sup> security holders who will not be sent new issue documents
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue

+ See chapter 19 for defined terms.


- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of <sup>+</sup>security holders
- 25 If the issue is contingent on <sup>+</sup>security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do <sup>+</sup>security holders sell their entitlements *in full* through a broker?
- 31 How do <sup>+</sup>security holders sell part of their entitlements through a broker and accept for the balance?
- 32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Despatch date

\_\_\_\_\_

## Part 3 - Quotation of securities – Not Applicable

You need only complete this section if you are applying for quotation of securities



## Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indi	icate yo	u are	providing	the	information	or
documents						

If the *securities are *equity securities, the names of the 20 largest holders of the
additional +securities, and the number and percentage of additional +securities
held by those holders

If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories
 1,000
 1,001 - 5,000
 5,001 - 10,000
 100,001 - 100,000
 100,001 and over


37

35

A copy of any trust deed for the additional +securities

## Entities that have ticked box 34(b)

- 38 Number of securities for which <sup>+</sup>quotation is sought
- 39 Class of <sup>+</sup>securities for which quotation is sought



40 Do the <sup>+</sup>securities rank equally in all respects from the date of allotment with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in clause 38)

Number	+Class

+ See chapter 19	for defined terms.
------------------	--------------------

### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the *+*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

C. J. Campbell

Sign here:

..... Date: 12 November 2012 **Company Secretary** 

Print name:

Chris J Campbell

<sup>+</sup> See chapter 19 for defined terms.